This week's top news stories and latest developments
📈 Trending news from the industry
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease. Discover more.
The commercial production of recombinant proteins, such as antibodies and enzymes, relies on generating and maintaining specific cell lines designed to produce these specialised molecules. Read further >>>
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies. Discover more.
Transplant recipients of hematopoietic stem cells with a hereditary version of AD developed the disease at an accelerated rate. Discover more today >>>
Researchers have gained a deeper understanding of the neural biology of obesity, which could offer potential drug targets. Read more here.
💻 What to watch
In this webinar, esteemed experts will explore the latest breakthroughs in organoid technology and their application in early drug discovery for neurological conditions.
📅 Date: 29 May
Recommended by LinkedIn
⏰ Time: 15:00 BST
We are excited to delve into the role of organoids in advancing treatment of neurological disorders. Sign up here!
Join Dr Carleton Sage to learn about predicting ADME properties as a key approach to improving the efficiency of small molecule drug discovery. AI ADME model development approaches and case studies within drug discovery projects will be discussed.
📘 What to read
Download our latest report to gain insights into current research and future prospects from potential breakthroughs to global collaboration in pandemic preparedness.
What to listen to 🎧
In this episode, we explore the latest technological advancements in the field and more.
This conversation features Dr Luke Alderwick, Senior Group Leader in HTS/Hit ID at Early Discovery at Charles River Laboratories (CRL), and Dr Sachin Mahale, Research Leader in High Throughput Screening at Charles River Laboratories.
Sign up for free! 🖊️
Sign up here to stay ahead of all the latest breaking news, expert insights and the newest trends in global drug discovery.
Drug Target Review is an essential multimedia resource which is trusted and recognised globally of researchers and scientific leaders who cover the most up-to-date innovations, and cutting edge technologies in the industry.
Corporate Influencer Club
6moThank you Drug Target Review